Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Antonius Schuh
AddedMar 31, 2024
UpdatedMay 31, 2026
Antonius Schuh

Antonius Schuh

Board Member, Diogenix

Crunchbase

Antonius Schuh's Career

Diogenix
Diogenix
Board Member· Board
Selection
Selection

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Antonius Schuh's Career

Diogenix
Diogenix
Public$3.2M82007
Board Member· Board

Leadership at Diogenix

Cam GallagherCam GallagherFounder

Similar to Diogenix

NeodiagnostixNeodiagnostixRockville, MD, USDiagnostics, Genomicsest. 2005NeodiagnostixRockville, MD, US · est. 2005

NeoDiagnostix, a Maryland-based medical organization, pioneers personalized cancer care through advanced genomics and diagnostics.

Seed · $1.5M9
SenGenixSenGenixDurham, NC, USDiagnostic Testsest. 2012SenGenixDurham, NC, US · est. 2012

SenGenix: Developing fast, accurate, low-cost point-of-care diagnostic tests since 2012.

Series A · $11.2M6
ProteogenixProteogenixCosta Mesa, CA, USDiagnostic Testsest. 2002ProteogenixCosta Mesa, CA, US · est. 2002

ProteoGenix Inc. develops and commercializes diagnostic tests for pregnancy-related complications.

Series A · $39.2M30
SynapDxSynapDxLexington, MA, USDiagnostic Testsest. 2010SynapDxLexington, MA, US · est. 2010

SynapDX: Pioneering early autism detection through blood-based diagnostic tests.

Series B · $32.4M11
Selection
Selection
Series A$9.2M72017San Diego, CA, US
CEO· C-Suite · Management

Leadership at Selection

Andreas KlostermannAndreas KlostermannFounder
Christopher J. LarsonChristopher J. LarsonBoard Member

Similar to Selection

Selva TherapeuticsSelva TherapeuticsDel Mar, CA, USTherapeuticsest. 2017Selva TherapeuticsDel Mar, CA, US · est. 2017

Selva Therapeutics: A biotech firm specializing in COVID-19 and infectious disease therapies.

Series A · $3M4
Tr1xTr1xLos Angeles, CA, USCell Therapyest. 2018Tr1xLos Angeles, CA, US · est. 2018

Tr1x: Pioneering cellular therapies for autoimmune disorders, recalibrating the immune system for long-term tolerance.

Series A · $75M30
Tavotek BiotherapeuticsTavotek BiotherapeuticsGwynedd, PA, USBiopharmaceuticals, Therapeuticsest. 2019Tavotek BiotherapeuticsGwynedd, PA, US · est. 2019

Tavotek: A biopharmaceutical company innovating therapies for oncology and autoimmune diseases.

Series B · $55M24
Lytica TherapeuticsLytica TherapeuticsCambridge, MA, USPeptides, Therapeuticsest. 2019Lytica TherapeuticsCambridge, MA, US · est. 2019

Lytica Therapeutics, Inc.: A biotech firm specializing in novel peptide therapeutics development.

Series A · $5.3M10

Antonius Schuh's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Antonius Schuh

Kevin OwensKevin OwensBoard Member · GbicBrian MartinezBrian MartinezCo-Founder & CEO · Demo LessonWarren HebardWarren HebardBoard Member · iSelectKevin J. CameronKevin J. CameronCo-Founder & CEO · IonetixAnthony LandoAnthony LandoCEO · Innovation FactoryBadal PatelBadal PatelBoard Member · Pillir